| Erlotinib in previously treated non–small-cell lung cancer FA Shepherd, J Rodrigues Pereira, T Ciuleanu, EH Tan, V Hirsh, ... New England journal of medicine 353 (2), 123-132, 2005 | 7361 | 2005 |
| Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group JP Pignon, H Tribodet, GV Scagliotti, JY Douillard, FA Shepherd, ... Journal of clinical oncology 26 (21), 3552-3559, 2008 | 3295 | 2008 |
| iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ... The Lancet Oncology 18 (3), e143-e152, 2017 | 2577 | 2017 |
| Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer T Winton, R Livingston, D Johnson, J Rigas, M Johnston, C Butts, ... New England Journal of Medicine 352 (25), 2589-2597, 2005 | 2405 | 2005 |
| Erlotinib in lung cancer—molecular and clinical predictors of outcome MS Tsao, A Sakurada, JC Cutz, CQ Zhu, S Kamel-Reid, J Squire, ... New England Journal of Medicine 353 (2), 133-144, 2005 | 2360 | 2005 |
| RECIST 1.1—Update and clarification: From the RECIST committee LH Schwartz, S Litière, E De Vries, R Ford, S Gwyther, S Mandrekar, ... European journal of cancer 62, 132-137, 2016 | 2098 | 2016 |
| Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study Nature medicine 14 (8), 822-827, 2008 | 1205 | 2008 |
| Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models T Voskoglou-Nomikos, JL Pater, L Seymour Clinical cancer research 9 (11), 4227-4239, 2003 | 901 | 2003 |
| Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 CQ Zhu, G da Cunha Santos, K Ding, A Sakurada, JC Cutz, N Liu, ... Journal of clinical oncology 26 (26), 4268-4275, 2008 | 894 | 2008 |
| High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. WR Bezwoda, L Seymour, RD Dansey Journal of Clinical Oncology 13 (10), 2483-2489, 1995 | 545 | 1995 |
| Prognostic and predictive gene signature for adjuvant chemotherapy in resected non–small-cell lung cancer CQ Zhu, K Ding, D Strumpf, BA Weir, M Meyerson, N Pennell, RK Thomas, ... Journal of clinical oncology 28 (29), 4417-4424, 2010 | 526 | 2010 |
| Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non–small-cell lung cancer: updated survival analysis … CA Butts, K Ding, L Seymour, P Twumasi-Ankrah, B Graham, D Gandara, ... Journal of clinical oncology 28 (1), 29-34, 2010 | 515 | 2010 |
| Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of … MJ Moore, J Hamm, J Dancey, PD Eisenberg, M Dagenais, A Fields, ... Journal of clinical oncology 21 (17), 3296-3302, 2003 | 488 | 2003 |
| Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21 A Bezjak, D Tu, L Seymour, G Clark, A Trajkovic, M Zukin, J Ayoub, ... Journal of clinical oncology 24 (24), 3831-3837, 2006 | 476 | 2006 |
| ERCC1 isoform expression and DNA repair in non–small-cell lung cancer L Friboulet, KA Olaussen, JP Pignon, FA Shepherd, MS Tsao, S Graziano, ... New England Journal of Medicine 368 (12), 1101-1110, 2013 | 455 | 2013 |
| Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non–small-cell lung cancer MS Tsao, S Aviel-Ronen, K Ding, D Lau, N Liu, A Sakurada, M Whitehead, ... Journal of clinical oncology 25 (33), 5240-5247, 2007 | 453 | 2007 |
| A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line … FA Shepherd, J Pereira, TE Ciuleanu, EH Tan, V Hirsh, S Thongprasert, ... Journal of Clinical Oncology 22 (14_suppl), 7022-7022, 2004 | 415 | 2004 |
| RECIST 1.1–Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group LH Schwartz, L Seymour, S Litière, R Ford, S Gwyther, S Mandrekar, ... European journal of cancer 62, 138-145, 2016 | 412 | 2016 |
| Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer SS Sridhar, L Seymour, FA Shepherd The lancet oncology 4 (7), 397-406, 2003 | 410 | 2003 |
| Age and comorbidity as independent prognostic factors in the treatment of non–small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials TR Asmis, K Ding, L Seymour, FA Shepherd, NB Leighl, TL Winton, ... Journal of Clinical Oncology 26 (1), 54-59, 2008 | 403 | 2008 |
